Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GlaxoSmithKline's dividends per share for the
three
months ended in Sep. 2016 was E£0.00. Its dividends per share for the trailing twelve months (TTM) ended in Sep. 2016 was E£0.00. Its Dividend Payout Ratio for the
three
months ended in Sep. 2016 was 0.00. As of today, GlaxoSmithKline's Dividend Yield % is 0.24%.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.
GlaxoSmithKline Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
EGP 1.000000
2026-01-12
2026-01-13
2026-01-14
Cash Dividend
annually
EGP:EGP 1.000000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
GlaxoSmithKline's Dividend Yield (%) for Today is calculated as
Current Share Price is E£331.44.
GlaxoSmithKline's Dividends per Share for the trailing twelve months (TTM) ended in Today is E£1.
During the past 4 years, the highest Dividend Yield of GlaxoSmithKline was 0.82%. The lowest was 0.00%. And the median was 0.00%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GlaxoSmithKline Dividends per Share Related Terms
GlaxoSmithKline Dividends per Share Historical Data
* Premium members only.
The historical data trend for GlaxoSmithKline's Dividends per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, GlaxoSmithKline's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlaxoSmithKline Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where GlaxoSmithKline's Dividend Yield % falls into.
GlaxoSmithKline (CAI:BIOC) has a Dividends per Share of E£0.00 as of Sep. 2016. Dividends per share represents the per-share amount paid as dividends. View historical data on GlaxoSmithKline and its competitors.
Is GlaxoSmithKline's Dividends per Share too high?
GlaxoSmithKline's current Dividends per Share is E£0.00.
How does GlaxoSmithKline's Dividends per Share compare to PRPH?
GlaxoSmithKline's Dividends per Share of E£0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividends per Share for a Drug Manufacturers company?
A good Dividends per Share depends on the Drug Manufacturers industry context. However, Dividends per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividends per Share mean?
A high Dividends per Share can signal that a stock is expensive relative to its fundamentals. Dividends per share represents the per-share amount paid as dividends. View historical data on GlaxoSmithKline and its competitors. GlaxoSmithKline's current Dividends per Share is E£0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline stock overvalued right now?
GlaxoSmithKline (CAI:BIOC) has a current Dividends per Share of E£0.00. The current Dividends per Share is E£0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividends per Share calculated?
Dividends per Share is calculated from a company's financial statements. For GlaxoSmithKline (CAI:BIOC), the current Dividends per Share is E£0.00 as of Sep. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
GlaxoSmithKline is a pharmaceutical company. It is focused on developing new medicines in respiratory, HIV, oncology, and immune-inflation. The company is segmented into Commercial Operations and Total Research and development. It generates the majority of its revenue from the Commercial Operations segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:BIOC has been successfully added to your 
